Wiegering Verena, Frank Jana, Freudenberg Sandra, Morbach Henner, Schlegel Paul G, Eyrich Matthias, Winkler Beate
Department of Pediatric Haematology, Hemostaseology, Oncology and Stem Cell Transplantation.
Leuk Lymphoma. 2014 Apr;55(4):870-5. doi: 10.3109/10428194.2013.816423. Epub 2013 Jul 25.
Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity. Immune reconstitution was studied in a homogeneous cohort of 48 children with standard or medium risk ALL treated according to the ALL-Berlin-Frankfurt-Münster (BFM) protocol. Whereas the T-cell compartment was only moderately affected and recovered to normal levels quickly after treatment cessation, B-cells were significantly reduced during and after therapy. In particular, the naive B-cell compartment declined. Even 5 years after the end of therapy, B-cell distribution was disturbed and patients showed an ongoing reconstitution. Thus, even standard regimens for chemotherapy cause severe B-cell depletion that resolves only gradually.
儿童急性淋巴细胞白血病（ALL）的化疗是一种高效的治疗方法，但同时会对患者的免疫力造成显著抑制。在一个由48名按照ALL-柏林-法兰克福-明斯特（BFM）方案治疗的标准或中危ALL患儿组成的同质队列中，对免疫重建进行了研究。虽然T细胞区室仅受到中度影响，在治疗停止后能迅速恢复到正常水平，但B细胞在治疗期间和治疗后均显著减少。特别是幼稚B细胞区室下降。即使在治疗结束5年后，B细胞分布仍受到干扰，患者仍在持续进行免疫重建。因此，即使是标准的化疗方案也会导致严重的B细胞耗竭，且这种耗竭只能逐渐缓解。
